Effect of Intracameral Bevacizumab Injection on Corneal Endothelial Cells: In Vivo Evaluation

Purpose: To study the effect of intracameral Bevacizumab injection on the corneal endothelium and iris neovessels (INV). Methods: Ten eyes of 10 patients of average age 52.1± 13.17 years underwent intracameral Bevacizumab injection 1.25mg/0.05ml. Intraocular pressure, best corrected visual acuity, gonioscopy, neovascular membrane extent, anterior segment photography, iris fluorescein angiography and specular microscopy were recorded preoperatively and postoperatively. Results: The minimum follow-up period was 4 months. INVs started to regress in the first 2 days and regressed completely by the end of the fourth week. Reduction in INV leakage started one week after injection, resolving in 8 eyes (80%) by the end of the fourth week. IOP dropped from 17.8 mmHg ± 4.8 to 16.6 mmHg ± 2.8. The mean endothelial cell loss was 3.95% ± 6.78. Conclusion: ICB injection proved to be effective in producing regression of INV and proved to be safe on corneal endothelial cells.